Tocilizumab Treatment of COVID-19

The first part of this animation explains the inflammatory storm caused by an overactive immune response is the critical cause of mortality in severe COVID-19 patients. The second part demonstrates that the Tocilizumab treatment developed from the University of Science and Technology of China (USTC) has contributed to the fight against COVID-19.

Related research papers:

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients (https://academic.oup.com/nsr/advance-article/doi/10.1093/nsr/nwaa041/5804736)

Effective Treatment of Severe COVID-19 Patients with Tocilizumab (http://www.chinaxiv.org/abs/202003.00026)

Sourc:https://www.youtube.com/watch?v=LLOIhaVblKU